CLAIM AMENDMENTS

~~1. Use of the composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for inhibiting tau protein accumulation, aggregation, or tangle.~~

~~2 The use of claim 1, wherein the vector is a viral vector or a non-viral vector.~~

~~3. Use of the composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for inhibiting tau protein accumulation, aggregation, or tangle.~~

~~4. The use of claim 3, wherein the vector is a viral vector or a non-viral vector.~~

~~5. Use of the composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for inhibiting tau protein accumulation, aggregation, or tangle.~~

~~6. The use of claim 5, wherein the glia are astrocytes or microglia.~~

~~7. Use of the composition comprising neurons or glia having Nurr1 gene introduced thereinto in the manufacture of a medicament for inhibiting tau protein accumulation, aggregation, or tangle.~~

~~8. The use of claim 7, wherein the glia are astrocytes or microglia.~~

~~9~~1. Use of ~~the~~ a composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for ~~inhibiting~~ the treatment of tauopathy caused by tau protein phosphorylation.

~~10~~2. The use of claim ~~9~~1, wherein the vector is a viral vector or a non-viral vector.

~~11. Use of the composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for inhibiting tau protein phosphorylation.~~

~~12. The use of claim 11, wherein the vector is a viral vector or a non-viral vector.~~

~~13~~3. Use of ~~the~~ a composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for ~~inhibiting~~ the treatment of tauopathy caused by tau protein phosphorylation.

~~14~~4. The use of claim ~~1~~3, wherein the glia are astrocytes or microglia.

~~15. Use of the composition comprising neurons or glia having a Nurr1 gene introduced thereinto in the manufacture of a medicament for inhibiting tau protein phosphorylation.~~

~~16. The use of claim 15, wherein the glia are astrocytes or microglia.~~

~~17.~~5 Use of ~~the~~ a composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for ~~prevention or~~the treatment of ~~a disease~~tauopathy caused by tau protein accumulation, aggregation, or tangle.

~~18~~6. The use of claim ~~17~~5, wherein the vector is a viral vector or a non-viral vector.

~~19. Use of the composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for prevention or treatment of a disease caused by tau protein accumulation, aggregation, or tangle.~~

~~20. The use of claim 19, wherein the vector is a viral vector or a non-viral vector.~~

~~21~~7 Use of ~~the~~ a composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for the prevention or treatment of ~~a disease~~tauopathy caused by tau protein accumulation, aggregation, or tangle.

~~22~~8. The use of claim ~~21~~7, wherein the glia are astrocytes or microglia.

~~23. Use of the composition comprising neurons or glia having a Nurr1 gene introduced thereinto in the manufacture of a medicament for prevention or treatment of a disease caused by tau protein accumulation, aggregation, or tangle.~~

~~24. The use of claim 23, wherein the glia are astrocytes or microglia.~~

~~25. Use of the pharmaceutical composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for prevention or treatment of tauopathy.~~

~~26. Use of the pharmaceutical composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for prevention or treatment of tauopathy.~~

~~27. Use of the pharmaceutical composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for prevention or treatment of tauopathy.~~

~~28. Use of the pharmaceutical composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for prevention or treatment of tauopathy.~~

~~29~~9. The use of any one of claims ~~25 to 28~~1-8, wherein the tauopathy is a disease selected from the group consisting of tau-positive Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia (FTD), multi-Infarct dementia (MID), frontotemporal lobar degeneration (FTLD), progressive cupranuclear palsy (PSP), Pick’s disease, chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), globular glial tauopathy, Huntington's disease, ganglioglioma, gangliocytoma, primary age-related tauopathy (PART), argyrophilic grain disease, lead encephalopathy, lipofuscinosis, Lytico-Bodig disease, and meningioangiomatosis.